FindTrial
Sign In

Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)

Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029850
Enrollment
Unknown
Registered
2020-02-15
Start date
2020-02-15
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

experimental group:standardized comprehensive treatment combined with convalescent plasma treatment
control group:standardized comprehensive treatment

Sponsors

The First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
16 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR; 2. Aged > 18 years; 3. Written informed consent given by the patient or next-of-kin; 4. Clinical deterioration despite conventional treatment that required intensive care.

Exclusion criteria

Exclusion criteria: 1. Hypersensitive to immunoglobulin; 2. Have immunoglobulin A deficiency.

Design outcomes

Primary

MeasureTime frame
Fatality rate;—

Secondary

MeasureTime frame
ICU stay duration;Viral titers in respiratory samples;Hospital stay duration;incubation period;PaO2/FiO2;cytokines/chemokines;—

Countries

China

Contacts

Public ContactXiaowei Xu

The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease

xxw69@126.com+86 13605708066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026